Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CTH | P32929 | 1/20 | 0.36 |
| ▸ | CBS | P35520 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5854913 | 0.87 | SMN1; SMN2 (0.32) | TSHRCTHCBSTHPOSMN1; SMN2 | |
| SCHEMBL14556958 | 0.78 | TET2 (0.38) | — | |
| SCHEMBL20610349 | 0.76 | TSHR (0.33) | TSHRCTHCBSTHPOSMN1; SMN2 | |
| SCHEMBL30281304 | 0.76 | TSHR (0.33) | TSHRCTHCBSTHPOSMN1; SMN2 | |
| SCHEMBL30281290 | 0.76 | TSHR (0.33) | TSHRCTHCBSTHPOSMN1; SMN2 | |
| SCHEMBL11025847 | 0.72 | TSHR (0.31) | TSHRCTHCBSTHPOSMN1; SMN2 | |
| SCHEMBL11027378 | 0.72 | TSHR (0.31) | TSHRCTHCBSTHPOSMN1; SMN2 | |
| SCHEMBL23864923 | 0.72 | TSHR (0.31) | TSHR | |
| SCHEMBL2628554 | 0.70 | — | — | |
| Bicarbonate SCHEMBL31291057 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114502527-B | Synthesis method of sevoflurane | 鲁南贝特制药有限公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-114502527-A | Synthetic method of sevoflurane | 鲁南贝特制药有限公司 | 2022-05-13 | — | — | CN | disclosed |
| US-9826129-B2 | Near-infrared-ray-absorbing composition, near-infrared-ray cut filter using same, manufacturing method therefor, camera module, and manufacturing method therefor | FUJIFILM CORPORATION (JP) | 2017-11-21 | — | — | US | disclosed |
| US-9826129-B2 | Near-infrared-ray-absorbing composition, near-infrared-ray cut filter using same, manufacturing method therefor, camera module, and manufacturing method therefor | FUJIFILM CORPORATION (JP) | 2017-11-21 | — | — | US | disclosed |
| US-20160037034-A1 | NEAR-INFRARED-RAY-ABSORBING COMPOSITION, NEAR-INFRARED-RAY CUT FILTER USING SAME, MANUFACTURING METHOD THEREFOR, CAMERA MODULE, AND MANUFACTURING METHOD THEREFOR | FUJIFILM CORPORATION (JP) | 2016-02-04 | — | — | US | disclosed |
| US-20160037034-A1 | NEAR-INFRARED-RAY-ABSORBING COMPOSITION, NEAR-INFRARED-RAY CUT FILTER USING SAME, MANUFACTURING METHOD THEREFOR, CAMERA MODULE, AND MANUFACTURING METHOD THEREFOR | FUJIFILM CORPORATION (JP) | 2016-02-04 | — | — | US | disclosed |
| EP-2069278-B1 | PROCESS FOR THE PREPARATION OF CHLOROMETHYL 2,2,2-TRIFLUORO-1-(TRIFLUOROMETHYL) ETHYL ETHER | CRISTÁLIA PRODUTOS QUÍMICOS FARMACÊUTICOS LTDA (BR) | 2016-01-06 | — | — | EP | disclosed |
| US-8044247-B2 | Process for the preparation of fluoromethyl 2,2,2-trifluoro-1-(trifluoromethyl) ethyl ether | Cristália Produtos Químicos Farmacêuticos Ltda. (BR) | 2011-10-25 | — | — | US | disclosed |
| US-8039678-B2 | Process for the preparation of chloromethyl 2,2,2-trifluoro-1-(trifluoromethyl) ethyl ether | CRISTALIA PRODUTOS QUIMICOS FARMACEUTICOS LTDA. (BR) | 2011-10-18 | — | — | US | disclosed |
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-07-29 | — | — | US | disclosed |
| EP-2148869-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2010-02-03 | — | — | EP | disclosed |
| US-20100004490-A1 | PROCESS FOR THE PREPARATION OF CHLOROMETHYL 2,2,2-TRIFLUORO-1-(TRIFLUOROMETHYL) ETHYL ETHER | Cr1stalia Productos Quimicos Farmaceuticos LTDA (BR) | 2010-01-07 | — | — | US | disclosed |
| US-20090247791-A1 | PROCESS FOR THE PREPARATION OF FLUOROMETHYL 2,2,2-TRIFLUORO-1-(TRIFLUOROMETHYL) ETHYL ETHER | CRISTÁLIA PRODUTOS QUÍMICOS FARMACÊUTICOS LTDA (BR) | 2009-10-01 | — | — | US | disclosed |
| EP-2069278-A2 | PROCESS FOR THE PREPARATION OF CHLOROMETHYL 2,2,2-TRIFLUORO-1-(TRIFLUOROMETHYL) ETHYL ETHER | Cristália Produtos Químicos Farmacêuticos Ltda. (BR) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008130581-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008037039-A2 | PROCESS FOR THE PREPARATION OF CHLOROMETHYL 2,2,2-TRIFLUORO-1-(TRIFLUOROMETHYL) ETHYL ETHER | Cristália Produtos Químicos Farmacêuticos Ltda. (BR) | 2008-04-03 | — | — | WO | disclosed |
| EP-1286939-B1 | METHOD FOR FLUOROMETHYLATION OF ALCOHOLS VIA HALOGENATIVE DECARBOXYLATION | ABBOTT LAB (US) | 2006-02-15 | — | — | EP | disclosed |
| EP-1286939-A1 | METHOD FOR FLUOROMETHYLATION OF ALCOHOLS VIA HALOGENATIVE DECARBOXYLATION | Abbott Laboratories (US) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001094286-A1 | METHOD FOR FLUOROMETHYLATION OF ALCOHOLS VIA HALOGENATIVE DECARBOXYLATION | ABBOTT LABORATORIES (US) | 2001-12-13 | — | — | WO | disclosed |
| US-6271422-B1 | AN ALCOHOL IS REACTED WITH AN ALPHA-HALOESTER TO FORM AN ALPHA-ALKOXY ACID WHICH IS THEN DECARBOXYLATIVELY HALOGENATED TO FORM A CHLOROMETHYL ETHER. THE CHLOROMETHYL ETHER IS THEN CONVERTED TO THE DESIRED FLUORIDE | ABBOTT LABORATORIES | 2001-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004490-A1 | PROCESS FOR THE PREPARATION OF CHLOROMETHYL 2,2,2-TRIFLUORO-1-(TRIFLUOROMETHYL) ETHYL ETHER | PFDN2, PFAS, CA3 | TSHR 1594/4885CTH 37/4885CBS 520/4885 |
| US-20160037034-A1 | NEAR-INFRARED-RAY-ABSORBING COMPOSITION, NEAR-INFRARED-RAY CUT FILTER USING SAME, MANUFACTURING METHOD THEREFOR, CAMERA MODULE, AND MANUFACTURING METHOD THEREFOR | FAR1, SLC39A11, NOTUM | TSHR 3922/4885CTH 415/4885CBS 1846/4885 |
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GCGR, GPR65 | TSHR 1056/4885CTH 1580/4885CBS 1543/4885 |
| US-20090247791-A1 | PROCESS FOR THE PREPARATION OF FLUOROMETHYL 2,2,2-TRIFLUORO-1-(TRIFLUOROMETHYL) ETHYL ETHER | CA3, PFAS, PFDN2 | TSHR 822/4885CTH 206/4885CBS 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.